AstraZeneca, Daiichi Sankyo Partnered ADC Shows Promise In Hard-To-Treat Breast Cancer

  • AstraZeneca Plc AZN and Daiichi Sankyo DSNKY have announced an update from their second antibody-drug conjugate (ADC) program that is showing promise in hard-to-treat breast cancer.
  • The ADC, datopotamab deruxtecan, posted a 43% response rate and five confirmed complete or partial responses among 21 patients with triple-negative breast cancer, according to cohort data from the TROPION-PanTumor01 Phase 1 study presented at the virtual ESMO Breast annual meeting 2021.
  • The majority of those patients were treated with 6-mg doses of the drug, while two received an 8-mg high dose.
  • Five confirmed complete (CR) or partial responses (PR) were also seen, with four additional CR/PRs awaiting confirmation at the time of data cutoff on January 8. A disease control rate of 95% was also observed.
  • Meanwhile, the TNBC cohort reported zero cases of interstitial lung disease.
  • The drug combines an antibody targeting TROP2 that's conjugated using a stable linker with a potent topoisomerase I inhibitor payload. It has a lower drug-to-antibody ratio that Daiichi suggests should both boost cell-killing activity and limit side effects.
  • Price Action: AZN shares are trading 0.8% higher at $54.25 during the premarket session on the last check Monday, while DSNKY shares closed $25.86 on Friday
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareGeneralbreast cancerBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!